Form D · Biotechnology

OncoImmune, Inc.

Rockville, MD · CIK 0001695528

Offering snapshot reported May 22, 2020 · SEC filing

Reported sold
$3M
Offering amount: $3M
Investors reported
3
Form D · investor count
Minimum accepted
$10K
Reported outside-investor minimum
First sale
Mar 24, 2020
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$1.5M$3MApr 2, 2020: $750,000.00Apr 2, 2020May 22, 2020: $3,000,000.00May 22, 2020

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$750,000 → $3,000,000
  • Reported investors1 → 3

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 22, 2020Amendment$3,000,000$2,250,000vs Apr 2, 20203SEC filing
Apr 2, 2020Initial$750,000No comparison1SEC filing
Feb 7, 2017Initial$5,501,790No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-364168

Source: Form D, filed May 22, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Martin Devenport Executive
Gary Fanger Director
Kun Liang Guan Director
Miao Hong Director
Yang Liu Director, Executive
Karen Liu Director
Pan Zheng Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
9430 Key West Ave. Suite 113
Rockville, MD, 208507